The deal of the year could be arranged by Thanksgiving, or so goes the story. Despite opposition from politicians, despite the tricky nature of pulling off a tax inversion that size, Pfizer ($PFE) and Allergan ($AGN) may well be engaged before the month is out, giving Pfizer its long-sought tax reduction and its answer to the who-will-you-buy question that's popped up on every earnings call since AstraZeneca's ($AZN) final rejection last year.

And if Pfizer and Allergan do merge, that changes another question CEO Ian Read has faced since 2014, when he announced the company would consider a breakup. Would a megadeal delay that breakup decision past 2017? Or speed it up considerably?

Points to ponder as one wades through the deluge of coverage, from media and analysts alike, about the potential deal--price TBA--which would create a pharma leviathan with $66 billion in sales and a $330 billion market cap. Here's our collection.